A detailed history of Royce & Associates LP transactions in Silverback Therapeutics, Inc. stock. As of the latest transaction made, Royce & Associates LP holds 645,700 shares of SBTX stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
645,700
Previous 558,700 15.57%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
N/A
87,000 Added 15.57%
645,700 $0
Q1 2024

May 13, 2024

BUY
N/A
85,000 Added 17.94%
558,700 $0
Q4 2023

Feb 12, 2024

BUY
N/A
10,000 Added 2.16%
473,700 $0
Q2 2023

Aug 07, 2023

BUY
N/A
159,800 Added 52.58%
463,700 $0
Q1 2023

May 04, 2023

BUY
N/A
303,900 New
303,900 $1.98 Million

Others Institutions Holding SBTX

About Silverback Therapeutics, Inc.


  • Ticker SBTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,473,800
  • Description
  • Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...
More about SBTX
Track This Portfolio

Track Royce & Associates LP Portfolio

Follow Royce & Associates LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

News

Stay updated on Royce & Associates LP with notifications on news.